Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Exclusion Criteria

• •Prior radiation must not have included 30% or more of major bone-marrow containing areas, such as the pelvis and lumbar spine
• •Common Terminology Criteria Grade 2 or greater neuropathy
• •Inadequate hematologic, hepatic, or renal function
• •Known prior severe hypersensitivity reactions to agents containing Cremophor® EL or known hypersensitivity or prior intolerance to fluoropyrimidine
• •Known or suspected dihydropyrimidine dehydrogenase deficiency
• •More than 3 prior chemotherapy regimens in the metastatic setting
• •Prior treatment with an epothilone or lapatinib; prior treatment with capecitabine within the past 6 months